Elinogrel

• Description :

  Elinogrel (PRT060128) is a potent, direct acting, competitive, and reversible platelet P2Y12 antagonist (IC50=20 nM) . It is orally and intravenously available and has potent antiplatelet effects[1].

• CAS Number :

  [936500-94-6]

• Product Name Alternative :

  PRT060128

• UNSPSC :

  12352005

• Target :

  P2Y Receptor

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/elinogrel.html

• Purity :

  98.68

• Solubility :

  DMSO : 62.5 mg/mL (ultrasonic)

• Smiles :

  O=S(C1=CC=C(Cl)S1)(NC(NC2=CC=C(N3C(NC4=C(C=C(F)C(NC)=C4)C3=O)=O)C=C2)=O)=O

• Molecular Formula :

  C20H15ClFN5O5S2

• Molecular Weight :

  523.95

• References & Citations :

  [1]Angiolillo DJ, et al. Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudyfrom the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial. Circ Cardiovasc Interv. 2012 Jun;5 (3) :347-56.|[2]Jacobson KA, et al. Pharmacochemistry of the platelet purinergic receptors. Purinergic Signal. 2011 Sep;7 (3) :305-24.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• Isoform :

  P2Y12 Receptor